Preservation of quality of life in patients with human epidermal growth factor receptor 2–positive metastatic breast cancer treated with tucatinib or placebo when added to trastuzumab and capecitabine (HER2CLIMB trial)

European Journal of Cancer（2021）

引用 9|浏览18

暂无评分

摘要

•HR-QoL was preserved in HER2+ metastatic breast cancer patients on a tucatinib regimen.•HR-QoL was preserved longer in patients with brain metastases taking tucatinib.•Preserved HR-QoL was in context of improved progression-free and overall survival.

查看译文

关键词

Metastatic breast cancer,Human epidermal growth factor receptor 2 positive (HER2),Quality of life,Brain metastases,Tucatinib,Trastuzumab

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要